Altimmune (ALT) to Release Earnings on Tuesday

Key Points

• Altimmune (ALT) is set to release its Q2 2025 earnings on August 12, with analysts expecting a loss of ($0.30) per share and no revenue.
• Recently, Altimmune's stock price decreased by 1.5%, trading at $3.62, while several brokerage firms adjusted their ratings, indicating increased caution among analysts.
• Institutional investors have shown interest, with notable stakes increased by firms like MIRAE ASSET GLOBAL ETFS and Envestnet Asset Management, raising concerns about the stock's performance dynamics.

Altimmune (NASDAQ:ALT - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Altimmune to post earnings of ($0.30) per share and revenue of $0.00 million for the quarter.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.09. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 451,200.00% and a negative return on equity of 65.44%. During the same period in the prior year, the business posted ($0.34) earnings per share. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Stock Down 1.5%

Shares of Altimmune stock traded down $0.06 during trading on Wednesday, reaching $3.62. 1,774,702 shares of the stock were exchanged, compared to its average volume of 3,805,167. The stock's fifty day moving average is $5.06 and its 200 day moving average is $5.46. The firm has a market cap of $293.21 million, a price-to-earnings ratio of -2.87 and a beta of -0.01. Altimmune has a 1 year low of $2.90 and a 1 year high of $11.16.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ALT. JMP Securities dropped their target price on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a report on Thursday, July 10th. The Goldman Sachs Group upgraded shares of Altimmune to a "strong sell" rating in a report on Thursday, July 10th. William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday, June 27th. Wall Street Zen cut shares of Altimmune from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Altimmune in a research note on Friday, June 27th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Altimmune has an average rating of "Moderate Buy" and a consensus target price of $18.20.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock valued at $247,000 after acquiring an additional 2,241 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Altimmune by 48.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company's stock valued at $127,000 after purchasing an additional 10,671 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in Altimmune in the 1st quarter worth approximately $50,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.